Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: VIRACEPT

Summary for Tradename: VIRACEPT

Suppliers: see list5
patent expirations by year for

Pharmacology for Tradename: VIRACEPT

Drug ClassProtease Inhibitor
Mechanism of ActionHIV Protease Inhibitors

Clinical Trials for: VIRACEPT

A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
Status: Completed Condition: Solid Tumors

Nelfinavir, a Phase I/Phase II Rectal Cancer Study
Status: Active, not recruiting Condition: Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal

Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy
Status: Recruiting Condition: Multiple Myeloma

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Status: Completed Condition: HIV Infection

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Status: Not yet recruiting Condition: Myeloma

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea
Status: Terminated Condition: Diarrhea

Radical Lung Radiotherapy Plus Nelfinavir
Status: Withdrawn Condition: Lung Cancer

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer
Status: Recruiting Condition: Cervical Cancer

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
Status: Not yet recruiting Condition: Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Kaposi Sarcoma; Gastric Cancer; Nasopharyngeal Cancer; EBV; Castleman Disease

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients
Status: Suspended Condition: HIV Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
nelfinavir mesylate
POWDER;ORAL020778Mar 14, 1997DISCNNo5,484,926*PED<disabled>Y<disabled>
nelfinavir mesylate
POWDER;ORAL020778Mar 14, 1997DISCNNo5,952,343*PED<disabled>Y<disabled>
nelfinavir mesylate
POWDER;ORAL020778Mar 14, 1997DISCNNo6,162,812*PED<disabled>Y<disabled>
nelfinavir mesylate
TABLET;ORAL020779Mar 14, 1997RXYes5,484,926*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology